Multi-institutional prospective observational study of the effectiveness of eribulin in first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: The KBCRN A001: E-SPEC Study
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI